Fredun Pharmaceuticals Ltd vs Piramal Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 2401 as of 12 May 11:36 . The P/E Ratio of Fredun Pharmaceuticals Ltd changed from 16 on March 2025 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 325.4 on March 2025 to 991.5 on March 2024 . This represents a CAGR of 24.96% over 5 years The Market Cap of Fredun Pharmaceuticals Ltd changed from ₹ 315.67 crore on March 2025 to ₹ 0 crore on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 29763 crore on March 2025 to ₹ 17052 crore on March 2024 . This represents a CAGR of -10.54% over 5 years The revenue of Fredun Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 160.92 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The ebitda of Fredun Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 26.34 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 1.59 % on March 2025 . This represents a CAGR of -35.18% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years .

About Fredun Pharmaceuticals Ltd

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

FAQs for the comparison of Fredun Pharmaceuticals Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Fredun Pharmaceuticals Ltd or Piramal Pharma Ltd?

Market cap of Fredun Pharmaceuticals Ltd is 1,389 Cr while Market cap of Piramal Pharma Ltd is 24,464 Cr

What are the key factors driving the stock performance of Fredun Pharmaceuticals Ltd and Piramal Pharma Ltd?

The stock performance of Fredun Pharmaceuticals Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fredun Pharmaceuticals Ltd and Piramal Pharma Ltd?

As of May 12, 2026, the Fredun Pharmaceuticals Ltd stock price is INR ₹2520.9. On the other hand, Piramal Pharma Ltd stock price is INR ₹184.05.

How do dividend payouts of Fredun Pharmaceuticals Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Fredun Pharmaceuticals Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.